Logo image of CMMB

CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CMMB - US16385C2035 - ADR

2.48 USD
+0.01 (+0.4%)
Last: 12/5/2025, 8:11:11 PM
2.52 USD
+0.04 (+1.61%)
After Hours: 12/5/2025, 8:11:11 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CMMB. CMMB was compared to 534 industry peers in the Biotechnology industry. CMMB has a great financial health rating, but its profitability evaluates not so good. CMMB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CMMB had negative earnings in the past year.
In the past year CMMB has reported a negative cash flow from operations.
CMMB had negative earnings in each of the past 5 years.
In the past 5 years CMMB always reported negative operating cash flow.
CMMB Yearly Net Income VS EBIT VS OCF VS FCFCMMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of CMMB (-106.24%) is worse than 76.59% of its industry peers.
CMMB's Return On Equity of -121.90% is in line compared to the rest of the industry. CMMB outperforms 41.57% of its industry peers.
Industry RankSector Rank
ROA -106.24%
ROE -121.9%
ROIC N/A
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
CMMB Yearly ROA, ROE, ROICCMMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

CMMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMMB Yearly Profit, Operating, Gross MarginsCMMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

CMMB has more shares outstanding than it did 1 year ago.
CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMMB Yearly Shares OutstandingCMMB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
CMMB Yearly Total Debt VS Total AssetsCMMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 3.19 indicates that CMMB is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.19, CMMB is doing good in the industry, outperforming 69.10% of the companies in the same industry.
There is no outstanding debt for CMMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.19
ROIC/WACCN/A
WACCN/A
CMMB Yearly LT Debt VS Equity VS FCFCMMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 7.42 indicates that CMMB has no problem at all paying its short term obligations.
CMMB's Current ratio of 7.42 is fine compared to the rest of the industry. CMMB outperforms 72.47% of its industry peers.
A Quick Ratio of 7.42 indicates that CMMB has no problem at all paying its short term obligations.
CMMB has a Quick ratio of 7.42. This is in the better half of the industry: CMMB outperforms 72.85% of its industry peers.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.42
CMMB Yearly Current Assets VS Current LiabilitesCMMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

CMMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.82%, which is quite impressive.
EPS 1Y (TTM)92.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.66% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.09%
EPS Next 2Y39.32%
EPS Next 3Y24.42%
EPS Next 5Y14.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMMB Yearly Revenue VS EstimatesCMMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M
CMMB Yearly EPS VS EstimatesCMMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMMB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMMB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMMB Price Earnings VS Forward Price EarningsCMMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMMB Per share dataCMMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as CMMB's earnings are expected to grow with 24.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.32%
EPS Next 3Y24.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (12/5/2025, 8:11:11 PM)

After market: 2.52 +0.04 (+1.61%)

2.48

+0.01 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2025-11-17
Earnings (Next)03-02 2026-03-02/amc
Inst Owners15.9%
Inst Owner Change-90.77%
Ins Owners11.37%
Ins Owner Change0%
Market Cap46.76M
Revenue(TTM)N/A
Net Income(TTM)-11.82M
Analysts85
Price Target27.03 (989.92%)
Short Float %2.15%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.67%
PT rev (3m)205.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.82
P/tB 4.82
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.24%
ROE -121.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.42
Altman-Z 3.19
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)40.38%
Cap/Depr(5y)224.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.6%
EPS Next Y94.09%
EPS Next 2Y39.32%
EPS Next 3Y24.42%
EPS Next 5Y14.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.06%
OCF growth 3YN/A
OCF growth 5YN/A

CHEMOMAB THERAPEUTICS LTD / CMMB FAQ

Can you provide the ChartMill fundamental rating for CHEMOMAB THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 3 / 10 to CMMB.


What is the valuation status of CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

ChartMill assigns a valuation rating of 1 / 10 to CHEMOMAB THERAPEUTICS LTD (CMMB). This can be considered as Overvalued.


What is the profitability of CMMB stock?

CHEMOMAB THERAPEUTICS LTD (CMMB) has a profitability rating of 0 / 10.


What is the financial health of CHEMOMAB THERAPEUTICS LTD (CMMB) stock?

The financial health rating of CHEMOMAB THERAPEUTICS LTD (CMMB) is 8 / 10.